Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06603974
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-13
Brief Title:
The Efficacy and Safety of Benmelstobart for GCEGC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Study of Benmelstobart in Combination with Antiangiogenesis Drugs and Neoadjuvant Chemotherapy for Locally Progressive Gastric Cancer Gastroesophageal Junction Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EASOBFGE
Brief Summary:
The goal of this clinical trial is to evaluate the major pathological response MPR rate of locally advanced gastric cancer gastroesophageal junction cancer treated with bemosumab combined with antiangiogenic drugs and neoadjuvant chemotherapy
Researchers will use drug Benmelstobart in combination with antiangiogenesis drugs and newadjuvant chemotherapy to see if the drug works to treat locally advanced gastric cancer gastroesophageal junction cancer
Participants willinjection drug BenmelstobartOn the first day of each cycle 3 weeks 21 days were a treatment cycle
Researchers will use drug Benmelstobart in combination with antiangiogenesis drugs and newadjuvant chemotherapy to see if the drug works to treat locally advanced gastric cancer gastroesophageal junction cancer
Participants willinjection drug BenmelstobartOn the first day of each cycle 3 weeks 21 days were a treatment cycle
Detailed Description:
The phase iii clinical study of benmelstobart combined with anlotinib oxaliplatin and capecitabine in the first-line treatment of gastric gastroesophageal junction adenocarcinoma has shown good efficacy and safety Anti vascular drugs have also shown excellent anti-tumor effects in the neoadjuvant treatment of locally advanced gastric cancer Therefore this study plans to explore the efficacy of benmelstobart combined with anti angiogenic drugs and neoadjuvant chemotherapy for locally advanced gastric cancer gastroesophageal junction cancer and make up for this part of the treatment gap
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None